A method for producing partially deglycosylated HIV-1 envelope glycoproteins through site-directed mutagenesis

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		0806
IP Type:		Licensable Technology
Title:		A method for producing partially deglycosylated HIV-1 envelope glycoproteins through site-directed mutagenesis
Inventor:		Essex, Myron E
Summary:		MARKETS ADDRESSED: The invention provides for compositions of deglycosylated HIV-1 glycoproteins and for their administration to mammals for antibody production. INNOVATIONS & ADVANTAGES: This invention describes a method for producing partially deglycosylated HIV-1 envelope glycoproteins through site-directed mutagenesis. Removal of multiple carbohydrate residues by mutation of their consensus N-linkage sites exposes gp160/gp120 protein domains to the host immune system and may lead to enhanced immune response. Such mutated derivations of gp160/gp120 retain normal structure and function, as measured by infectivity of virions bearing the mutated proteins.
Tech Type:		Drug Discovery Tools \| Therapeutics - Drugs \| Drug Discovery Tools
URL:		http://otd.harvard.edu/technologies/tech.php?case=0806
Contact:		Vivian Berlin, (617) 496-0474
Organization:		Harvard University

Display all intellectual properties for Essex, Myron E
Display all intellectual properties for Harvard University